Evidence map›Paper›PMID 28560265›Full record

ArticleNPJ schizophrenia2017

Isoform specific differences in phospholipase C beta 1 expression in the prefrontal cortex in schizophrenia and suicide.

M Udawela, E Scarr, S Boer, J Y Um, A J Hannan, C McOmish, C C Felder, E A Thomas, B Dean

Open access · goldAbstract read
In one paragraph

Article in NPJ schizophrenia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Altered PLCβ/IPBiomedicines · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

M UdawelaMolecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.
E ScarrMolecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.
S BoerMolecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.
J Y UmMolecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.
A J HannanEpigenetics and Neural Plasticity Laboratory, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.
C McOmishMolecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.
C C FelderLilly Research Laboratories, Neuroscience Research Division, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN USA.
E A ThomasDepartment of Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, CA USA.
B DeanMolecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC Australia.
University of Melbourne · AUEli Lilly (United States) · USFlorey Institute of Neuroscience and Mental Health · AUNational Institute of Food and Drug Safety Evaluation · KRScripps Research Institute · US

Funding

Schizophrenia: Molecular Markers of Disease ProgressionR01MH069696 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI THOMAS, ELIZABETH A · 2004 to 2008
$1.5M
NIMH NIH HHS R01 MH069696
6 · The paper itself

Abstract

Our previous study demonstrated that phospholipase C beta 1 mRNA was down-regulated in Brodmann's area 46 from subjects with schizophrenia. However, phospholipase C beta 1 protein has also been shown to be lower in Brodmann's area 8 and 9 from teenage suicide subjects, creating a potential confound in interpreting the findings in schizophrenia due to the high suicide rate associated with this disorder. To begin to reconcile and consolidate these findings, in this study, we measured mRNA and protein levels of phospholipase C beta 1 variants a and b in Brodmann's area 46 and Brodmann's area 9 from subjects with schizophrenia, many of whom were suicide completers, and determined the diagnostic specificity of observed findings. Consistent with our previous study, levels of phospholipase C beta 1 a and b mRNA, but not protein, were lower in Brodmann's area 46 from subjects with schizophrenia. In Brodmann's area 9, phospholipase C beta 1a protein levels were lower in subjects with schizophrenia, while phospholipase C beta 1b mRNA was higher and protein was lower in those that had died of suicide. Altered protein levels in Brodmann's area 9 appeared to be diagnostically specific, as we did not detect these changes in subjects with bipolar disorder, major depressive disorder or suicide completers with no diagnosis of mental illness. We further assessed the relationship between phospholipase C beta 1 and levels of muscarinic receptors (CHRMs) that signal through this protein, in both human and

Identifiers

PMID28560265
PMCPMC5441535
OpenAlexW2605701882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.